Cancer diagnostic panel

• US 7,348,142 B2
• Filed: 03/21/2003
• Issued: 03/25/2008
• Est. Priority Date: 03/29/2002
• Status: Expired due to Fees

• Current Assignee: Lcc Veridex
• Original Assignee: Lcc Veridex
• Inventors: Wang, Yixin
• Primary Examiner(s): WHISENANT, ETHAN C
• Application Number:
  US10/393,567
• Publication Number:
  US 20030194733A1
• Time in Patent Office: 1,831 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

A method of diagnosing cancer by identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from two groups of genes.

Gene expression portfolios and kits for employing the method are further aspects of the invention.

Claims

1. A method of diagnosing prostate, breast, colon, lung or ovarian cancer comprising identifying from a cell from a human patient, the differential modulation of each gene (relative to the expression of the same genes in a normal population) in a gene expression portfolio selected for use with peripheral blood samples and wherein the genes of said portfolio consist of those having Seq. ID. No. 32-37, 69, and 98-100 or which express products having such sequences, and comparing such modulation with that of the same genes found in cells associated with human prostate, breast, colon, lung, or ovarian cancers;

and diagnosing the patient as having prostate, breast, colon, lung or ovarian cancer if the modulation of the gene expression portfolio of the patient is the same as that of the genes found in cells associated with prostate, breast, colon, lung or ovarian cancer and diagnosing the patient as not having prostate, breast, colon, lung or ovarian cancer if the modulation of the gene expression portfolio of the patient is not the same as that of the genes found in cells associated with prostate, breast, colon, lung or ovarian cancer.

2. The method of claim 1 wherein there is at least a 2 fold difference in the expression of the modulated genes.

3. The method of claim 1 wherein the p-value indicating differential modulation is less than 0.05.